Log in

NASDAQ:DXCMDexCom Stock Price, Forecast & News

$407.35
+7.14 (+1.78 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$398.06
Now: $407.35
$415.48
50-Day Range
$344.85
MA: $389.82
$417.73
52-Week Range
$138.28
Now: $407.35
$428.59
Volume1.08 million shs
Average Volume1.30 million shs
Market Capitalization$37.62 billion
P/E Ratio256.19
Dividend YieldN/A
Beta0.79
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More
DexCom logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.48 billion
Cash Flow$2.39 per share
Book Value$9.64 per share

Profitability

Net Income$101.10 million

Miscellaneous

Employees3,900
Market Cap$37.62 billion
Next Earnings Date7/28/2020 (Confirmed)
OptionableOptionable

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

DexCom (NASDAQ:DXCM) Frequently Asked Questions

How has DexCom's stock been impacted by COVID-19 (Coronavirus)?

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM stock has increased by 61.4% and is now trading at $407.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DexCom?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DexCom.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for DexCom.

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings data on Tuesday, April, 28th. The medical device company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.15 by $0.29. The medical device company had revenue of $405.10 million for the quarter, compared to analysts' expectations of $358.34 million. DexCom had a net margin of 9.24% and a return on equity of 26.44%. DexCom's quarterly revenue was up 44.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) earnings per share. View DexCom's earnings history.

What price target have analysts set for DXCM?

21 analysts have issued 1 year price targets for DexCom's stock. Their forecasts range from $190.00 to $500.00. On average, they expect DexCom's stock price to reach $347.65 in the next year. This suggests that the stock has a possible downside of 14.7%. View analysts' price targets for DexCom.

Has DexCom been receiving favorable news coverage?

News headlines about DXCM stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. DexCom earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about DexCom.

Are investors shorting DexCom?

DexCom saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 4,770,000 shares, a drop of 16.8% from the May 31st total of 5,730,000 shares. Based on an average daily volume of 1,920,000 shares, the days-to-cover ratio is currently 2.5 days. Currently, 5.3% of the shares of the company are short sold. View DexCom's Current Options Chain.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), ServiceNow (NOW) and Shopify (SHOP).

Who are DexCom's key executives?

DexCom's management team includes the following people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
  • Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
  • Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $407.35.

How big of a company is DexCom?

DexCom has a market capitalization of $37.62 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.